Bio-Techne Corporation (T1CH34.SA)
| Previous close | 14.20 |
| Open | 0.00 |
| Bid | 13.53 x N/A |
| Ask | 13.61 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 114 |
| Market cap | 67.131B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 64.55 |
| EPS (TTM) | 0.22 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | 0.04 (0.27%) |
| Ex-dividend date | 10 May 2024 |
| 1y target est | N/A |
PR NewswireBIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences:
- PR Newswire
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) assays. By simplifying charge
- PR Newswire
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT).
